6:01 PM
 | 
Dec 14, 2011
 |  BC Extra  |  Company News

Wilex: FDA offers adcomm for Redectane

Wilex AG (Xetra:WL6) said it accepted an offer from FDA to participate in an advisory committee meeting to discuss the development and regulatory pathway of kidney cancer diagnostic Redectane. Wilex said FDA made the offer at a...

Read the full 174 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >